Federal Circuit Temporarily Halts ITC's Ban of Botox Rival Jeuveau

The U.S. Court of Appeals for the Federal Circuit ordered the delay of a ban on imports of a rival product to Allergan's Botox. The day before the 21-month limited exclusion order was to take effect on South Korean company Daewoong Pharmaceutical's anti-wrinkle treatment Jeuveau, the court temporarily halted the International Trade Commission's ban while the case is being heard. Any oppositions to the motion -- a position held by Allergan and its Korean partner Medytox -- are due by March 2, and any support of the delay must be submitted by March 5. The exclusion order stems from an ITC investigation into allegations that imports of botulinum toxin products violate Section 337 by way of theft of Medytox's and Allergan's trade secrets (see 1903080013). Daewoong and its U.S. subsidiary Evolus oppose the ban, claiming that the ITC has weaponized these investigations against rival manufacturers even when no violation of U.S. law has been committed. “Evolus is pleased with this decision as it allows us to continue to sell Jeuveau® to our customers without interruption,” a spokesperson for Evolus said.